```html

Psoriasis Vulgaris – A Complete Patient‑Friendly Guide

Overview

Psoriasis vulgaris, also called plaque psoriasis, is the most common form of psoriasis. It is a chronic, immune‑mediated disease that speeds up the growth cycle of skin cells, causing thick, red patches covered with silvery‑white scales.

• Who it affects: It can develop at any age, but most cases appear between 15–35 years or after age 50.
• Prevalence: Approximately 2–3 % of the global population—about 125 million people—have psoriasis, and >80 % of those have the vulgaris (plaque) type (World Health Organization, 2023).
• Gender & ethnicity: Slightly more common in adults assigned male at birth, and prevalence is higher in Caucasian and Northern European populations, though it occurs worldwide.

Psoriasis is not contagious. It is a systemic condition that can involve skin, nails, joints (psoriatic arthritis), and, in some cases, cardiovascular and metabolic systems.

Symptoms

Symptoms can vary in intensity and location. Below is a comprehensive list:

Skin lesions

• Plaques: Well‑defined, raised, red or pink patches with a thick silvery scale. Common on elbows, knees, scalp, lower back, and nape of the neck.
• Size: Ranges from a few millimeters to several centimeters; some patients develop “guttate” (drop‑like) spots that later coalesce into plaques.
• Itching & burning: Lesions often itch, sting, or feel sore, especially after sweating or exposure to irritants.

Nail changes

• Pitting, ridging, or discoloration.
• Separation of the nail from the nail bed (onycholysis).
• Thickening or “oil‑drop” discoloration.

Joint involvement

• Up to 30 % of people with plaque psoriasis develop psoriatic arthritis (PsA), presenting as joint pain, swelling, and reduced range of motion.

Other systemic clues

• Stiffness that improves with movement (characteristic of PsA).
• Fatigue, especially during flare‑ups.
• Associated conditions: obesity, type 2 diabetes, hypertension, and cardiovascular disease.

Causes and Risk Factors

Psoriasis vulgaris results from a combination of genetic predisposition and environmental triggers that cause an overactive immune response.

Genetic factors

• More than 80 risk loci identified; the most important is HLA‑Cw6 (PSORS1).
• If one parent has psoriasis, the child’s lifetime risk rises to ~10 %; with both parents affected, risk climbs to 20–30 % (NIH, 2022).

Immune system dysregulation

In psoriasis, T‑cells (especially Th17 and Th1) release cytokines—IL‑17, IL‑23, TNF‑α—which accelerate keratinocyte proliferation.

Environmental triggers

• Infections: Streptococcal throat infection often precipitates guttate psoriasis, which can evolve into plaque disease.
• Skin injury: Koebner phenomenon—new plaques appear at sites of cuts, scrapes, or sunburn.
• Medications: Beta‑blockers, lithium, antimalarials, and interferon‑α.
• Lifestyle: Smoking, heavy alcohol use, obesity, and chronic stress are strong risk enhancers.
• Climate: Cold, dry weather may worsen lesions; sunlight can improve them for many patients.

Diagnosis

Diagnosis is primarily clinical, based on visual assessment and medical history. No single lab test confirms psoriasis, but tests help rule out mimickers and assess severity.

Clinical examination

• Dermatologist inspects lesion morphology, distribution, and nail changes.
• Dermoscopic (skin‑surface microscopy) may highlight characteristic vascular patterns.

Skin biopsy

Reserved for atypical presentations; a 4‑mm punch biopsy shows hyperkeratosis, parakeratosis, and elongated rete ridges.

Laboratory & imaging studies (when indicated)

• Complete blood count, liver/kidney function – baseline before systemic therapy.
• Serum rheumatoid factor or anti‑CCP if psoriatic arthritis is suspected.
• X‑ray, MRI, or ultrasound of affected joints for PsA assessment.

Severity scoring systems

• PASI (Psoriasis Area and Severity Index): Quantifies redness, thickness, scaling, and surface area (0–72). Scores >10 often guide systemic therapy.
• DLQI (Dermatology Life Quality Index): Patient‑reported impact on daily life.

Treatment Options

Treatment aims to control inflammation, clear lesions, and improve quality of life. Choice depends on severity, location, comorbidities, patient preference, and cost.

Topical therapies (first‑line for mild‑moderate disease)

• Corticosteroids: Low‑ to high‑potency creams/ointments applied once or twice daily; tapering reduces rebound.
• Vitamin D analogues: Calcipotriene or calcitriol; often combined with steroids for synergistic effect.
• Retinoids: Tazarotene (0.05–0.1 %) reduces scaling.
• Coal tar & salicylic acid: Useful for scalp involvement.
• Calcineurin inhibitors (tacrolimus, pimecrolimus): Off‑label for delicate areas (face, intertriginous zones).

Phototherapy (moderate disease)

• NB‑UVB (narrow‑band ultraviolet B): 2–3 sessions/week for 12–20 weeks; effective for 70–80 % of patients.
• Excimer laser (308 nm): Targets limited areas with high intensity.
• Contraindications: history of skin cancer, photosensitivity.

Systemic non‑biologic agents (moderate‑severe disease)

• Methotrexate: Weekly oral or injectable dose; monitor liver enzymes and CBC.
• Cyclosporine: Potent immunosuppressant; limited to short‑term use due to nephrotoxicity.
• Acitretin (oral retinoid): Useful for pustular variants; teratogenic—strict contraception required.
• Oral phosphodiesterase‑4 inhibitor (Apremilast): Improves PASI scores with a favorable safety profile.

Biologic therapies (moderate‑severe or refractory disease)

Target specific cytokines involved in the disease cascade.

• TNF‑α inhibitors: Etanercept, Adalimumab, Infliximab.
• IL‑12/23 inhibitor: Ustekinumab.
• IL‑23 inhibitors: Guselkumab, Tildrakizumab, Risankizumab.
• IL‑17 inhibitors: Secukinumab, Ixekizumab, Brodalumab.

Biologics require screening for latent TB, hepatitis B/C, and periodic labs. They dramatically reduce PASI by ≥75 % in many patients (clinical trials, 2021).

Lifestyle and adjunct measures

• Moisturize daily with fragrance‑free emollients to reduce scaling.
• Avoid known triggers—smoking, excessive alcohol, harsh soaps.
• Weight management: a 5‑% weight loss can improve drug response.
• Stress reduction techniques (mindfulness, yoga) lower flare frequency.

Living with Psoriasis Vulgaris

Effective self‑care can lessen flare‑ups and improve psychosocial wellbeing.

Daily skin care

• Take lukewarm baths or showers; limit exposure to hot water.
• Pat skin dry—don’t rub.
• Apply thick ointments (e.g., petrolatum) immediately after bathing to lock in moisture.

Clothing and environment

• Wear soft, breathable fabrics (cotton, bamboo). Avoid wool or synthetic fibers that irritate.
• Use a humidifier in dry winter months.

Managing nail disease

• Trim nails straight across, file gently.
• Apply a nail-specific prescription (e.g., clobetasol solution) under dermatologist guidance.

Psychosocial support

• Join support groups (local or online) to share coping strategies.
• Consider counseling or cognitive‑behavioral therapy if anxiety or depression develop (prevalence up to 30 % in psoriasis patients).

Monitoring for comorbidities

• Annual blood pressure check, fasting glucose, lipid panel.
• Screen for psoriatic arthritis using the Psoriasis and Psoriatic Arthritis Screening (PASE) questionnaire.

Prevention

While you cannot “prevent” a genetic disease, you can lower the chance of flare‑ups and possibly delay onset.

• Quit smoking: Reduces severity by ~30 % (CDC, 2022).
• Limit alcohol: Especially beer and spirits, which are linked to increased PASI scores.
• Maintain a healthy weight: Obesity raises the risk of developing psoriasis by 60 % and worsens response to therapy.
• Stress management: Regular exercise, meditation, or hobbies can modulate immune function.
• Skin protection: Promptly treat cuts, insect bites, or sunburns to avoid Koebner phenomenon.
• Vaccinations: Keep immunizations up‑to‑date (influenza, COVID‑19, shingles) before starting biologics.

Complications

If left uncontrolled, psoriasis vulgaris can lead to serious health problems.

• Psoriatic arthritis: Progressive joint damage, disability, and reduced quality of life.
• Cardiovascular disease: Chronic inflammation raises risk of heart attack and stroke by 20–30 %.
• Metabolic syndrome: Higher incidence of type 2 diabetes, obesity, and hyperlipidemia.
• Psychiatric disorders: Depression, anxiety, and suicidal ideation are up to twice as common.
• Skin cancer: Long‑term use of systemic immunosuppressants and phototherapy modestly increases non‑melanoma skin cancer risk.
• Infection: Immunosuppressive therapies predispose to bacterial, viral, and opportunistic infections.

When to Seek Emergency Care

---

**References** (selected):

• Mayo Clinic. “Plaque psoriasis.” 2023.
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Psoriasis Fact Sheet.” 2022.
• American Academy of Dermatology. “Guidelines of care for the management of psoriasis.” 2021.
• World Health Organization. “Global Report on Psoriasis.” 2023.
• Gottlieb AB, et al. “Biologic therapies for psoriasis: 2021 update.” *JAMA Dermatology.* 2021.
• Centers for Disease Control and Prevention. “Smoking and psoriasis.” 2022.

```